Spyre Stock Based Compensation vs Begin Period Cash Flow Analysis

SYRE Stock   27.27  0.38  1.37%   
Spyre Therapeutics financial indicator trend analysis is much more than just breaking down Spyre Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spyre Therapeutics is a good investment. Please check the relationship between Spyre Therapeutics Stock Based Compensation and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

Stock Based Compensation vs Begin Period Cash Flow

JavaScript chart by amCharts 3.21.152014201620182020202220246M8M10M12M14M16M18M20M22M24M 15M20M25M30M35M40M45M50M55M60M65M70M75M80M85M
JavaScript chart by amCharts 3.21.15Stock Based Compensationtotal: 112.5MBegin Period Cash Flowtotal: 404.9M

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spyre Therapeutics Stock Based Compensation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have almost no relationship.
Stock Based CompensationBegin Period Cash FlowDiversified AwayStock Based CompensationBegin Period Cash FlowDiversified Away100%
The correlation between Spyre Therapeutics' Stock Based Compensation and Begin Period Cash Flow is 0.16. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Spyre Therapeutics, assuming nothing else is changed. The correlation between historical values of Spyre Therapeutics' Stock Based Compensation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Spyre Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Spyre Therapeutics' Stock Based Compensation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.16
Relationship DirectionPositive 
Relationship StrengthInsignificant

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Spyre Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 77.9 M, whereas Tax Provision is projected to grow to (24.7 K).
 2021 2022 2023 2024 (projected)
Interest Income111K837K6.1M6.5M
Net Interest Income111K837K6.1M6.5M

Spyre Therapeutics fundamental ratios Correlations

0.870.730.79-0.08-0.01-0.79-0.910.290.95-0.06-0.15-0.921.0-0.490.940.950.970.190.910.981.00.910.97-0.95-0.56
0.870.780.53-0.06-0.03-0.45-0.920.370.74-0.020.06-0.860.86-0.520.930.920.910.340.890.930.860.890.9-0.92-0.75
0.730.780.770.430.32-0.35-0.870.660.550.460.27-0.490.7-0.550.810.820.670.520.860.730.710.850.63-0.64-0.26
0.790.530.770.140.18-0.75-0.70.30.750.14-0.13-0.490.78-0.420.690.730.680.110.710.70.780.70.67-0.64-0.13
-0.08-0.060.430.140.570.25-0.160.79-0.251.00.60.28-0.13-0.230.060.02-0.250.720.23-0.15-0.130.2-0.30.310.63
-0.01-0.030.320.180.570.14-0.010.58-0.150.53-0.10.17-0.03-0.32-0.050.11-0.160.110.06-0.09-0.040.04-0.180.220.47
-0.79-0.45-0.35-0.750.250.140.590.12-0.930.250.450.7-0.810.39-0.64-0.58-0.750.07-0.59-0.72-0.8-0.59-0.760.720.33
-0.91-0.92-0.87-0.7-0.16-0.010.59-0.42-0.8-0.2-0.20.81-0.890.57-0.99-0.91-0.89-0.54-0.99-0.93-0.9-0.99-0.870.880.53
0.290.370.660.30.790.580.12-0.420.040.80.41-0.140.24-0.320.350.470.160.550.470.250.250.450.11-0.090.26
0.950.740.550.75-0.25-0.15-0.93-0.80.04-0.24-0.33-0.90.96-0.450.850.810.940.040.790.920.960.80.94-0.92-0.57
-0.06-0.020.460.141.00.530.25-0.20.8-0.240.650.25-0.11-0.250.110.05-0.210.760.27-0.12-0.10.24-0.260.270.59
-0.150.060.27-0.130.6-0.10.45-0.20.41-0.330.650.21-0.19-0.070.13-0.01-0.180.830.22-0.12-0.180.21-0.220.180.22
-0.92-0.86-0.49-0.490.280.170.70.81-0.14-0.90.250.21-0.930.39-0.87-0.87-0.95-0.13-0.8-0.94-0.93-0.81-0.950.940.7
1.00.860.70.78-0.13-0.03-0.81-0.890.240.96-0.11-0.19-0.93-0.470.930.940.980.150.890.981.00.890.97-0.96-0.58
-0.49-0.52-0.55-0.42-0.23-0.320.390.57-0.32-0.45-0.25-0.070.39-0.47-0.55-0.45-0.44-0.45-0.59-0.47-0.47-0.54-0.410.420.23
0.940.930.810.690.06-0.05-0.64-0.990.350.850.110.13-0.870.93-0.550.920.930.470.980.960.930.990.91-0.92-0.59
0.950.920.820.730.020.11-0.58-0.910.470.810.05-0.01-0.870.94-0.450.920.920.260.910.950.940.910.91-0.89-0.53
0.970.910.670.68-0.25-0.16-0.75-0.890.160.94-0.21-0.18-0.950.98-0.440.930.920.130.870.990.980.881.0-0.99-0.73
0.190.340.520.110.720.110.07-0.540.550.040.760.83-0.130.15-0.450.470.260.130.570.20.160.550.08-0.110.11
0.910.890.860.710.230.06-0.59-0.990.470.790.270.22-0.80.89-0.590.980.910.870.570.910.891.00.84-0.84-0.45
0.980.930.730.7-0.15-0.09-0.72-0.930.250.92-0.12-0.12-0.940.98-0.470.960.950.990.20.910.980.920.99-0.98-0.69
1.00.860.710.78-0.13-0.04-0.8-0.90.250.96-0.1-0.18-0.931.0-0.470.930.940.980.160.890.980.90.97-0.96-0.58
0.910.890.850.70.20.04-0.59-0.990.450.80.240.21-0.810.89-0.540.990.910.880.551.00.920.90.85-0.86-0.47
0.970.90.630.67-0.3-0.18-0.76-0.870.110.94-0.26-0.22-0.950.97-0.410.910.911.00.080.840.990.970.85-1.0-0.75
-0.95-0.92-0.64-0.640.310.220.720.88-0.09-0.920.270.180.94-0.960.42-0.92-0.89-0.99-0.11-0.84-0.98-0.96-0.86-1.00.79
-0.56-0.75-0.26-0.130.630.470.330.530.26-0.570.590.220.7-0.580.23-0.59-0.53-0.730.11-0.45-0.69-0.58-0.47-0.750.79
Click cells to compare fundamentals

Spyre Therapeutics Account Relationship Matchups

Spyre Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets83.2M161.6M109.9M71.1M341.9M359.0M
Other Current Liab14.8M464K14.0M12.8M31.1M32.6M
Total Current Liabilities18.4M16.4M20.1M14.7M32.0M16.7M
Total Stockholder Equity60.1M139.8M83.9M50.3M184.0M96.1M
Property Plant And Equipment Net1.0M7.2M9.9M8.4M6.7M0.0
Net Debt(14.1M)(84.6M)(10.1M)(30.2M)(104.3M)(99.1M)
Retained Earnings(195.1M)(276.0M)(341.8M)(425.6M)(764.4M)(726.2M)
Accounts Payable3.2M2.3M3.3M677K896K1.6M
Cash19.3M90.1M15.1M34.9M188.9M198.3M
Non Current Assets Total8.7M11.8M11.0M8.9M331K314.5K
Non Currrent Assets Other11K115K842K683K9K8.6K
Cash And Short Term Investments71.9M146.3M93.1M55.7M339.3M356.2M
Net Receivables3.1M300K815K375K337.5K320.6K
Common Stock Shares Outstanding1.3M2.1M2.6M3.4M6.9M7.2M
Short Term Investments52.7M56.2M78.0M20.8M150.4M157.9M
Liabilities And Stockholders Equity83.2M161.6M109.9M71.1M341.9M359.0M
Non Current Liabilities Total4.7M5.3M5.8M6.2M125.9M132.2M
Other Current Assets2.6M3.5M4.9M6.2M2.3M3.4M
Other Stockholder Equity255.1M415.8M425.8M476.0M763.2M801.4M
Total Liab23.1M21.8M26.0M20.8M157.8M165.7M
Total Current Assets74.5M149.8M98.9M62.3M341.5M358.6M
Accumulated Other Comprehensive Income51K11K(20K)(48K)302K317.1K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(37.90)
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…